Literature DB >> 6895663

Retrolental fibroplasia and blood transfusion in very low-birth-weight infants.

L M Sacks, D B Schaffer, E K Anday, G J Peckham, M Delivoria-Papadopoulos.   

Abstract

The relative contribution of transfusions of adult blood to the development of retrolental fibroplasia (RLF) in very low-birth-weight infants was examined. Five years of experience with the expanded use of replacement and exchange transfusions in 90 infants with birth weight less than or equal to 1,250 gm was reviewed. Twenty percent of the infants developed cicatricial RLF. Exchange transfusion was not related to development of cicatricial RLF. The incidence of RLF in infants receiving greater or equal to 130 ml of packed red blood cells per kilogram of birth weight as replacement blood transfusion (RBT) was significantly higher (42.9%) than that in infants receiving 61 to 131 ml of packed red blood cells per kilogram (15.4%) and infants receiving less than or equal to 60 ml of packed red blood cells per kilogram (0%), P less than .001. The need for RBT, however, was strongly correlated (r = .85, P less than .001) with increasing duration of O2 therapy. When O2 therapy was controlled for, the association between RBT and RLF did not achieve statistical significance (P = .07). The association between RBT and RLF remained significant when adjusted for duration of therapy in fractional inspired oxygen (FIO2) greater than 0.4. Further detailed studies of large numbers of susceptible infants are warranted to assess the magnitude of the contribution of transfusions of adult blood to development of RLF.

Entities:  

Mesh:

Year:  1981        PMID: 6895663

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  16 in total

1.  Effect of blood transfusion on lipid peroxidation in preterm infants.

Authors:  S P Wardle; J Drury; R Garr; A M Weindling
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-01       Impact factor: 5.747

2.  An elevated level of copper zinc superoxide dismutase fails to prevent oxygen induced retinopathy in mice.

Authors:  C Klaeger; L de Sa; A J Klaeger; E J Carlson; W V Good; C J Epstein
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

3.  Blood transfusion increases radical promoting non-transferrin bound iron in preterm infants.

Authors:  K Hirano; T Morinobu; H Kim; M Hiroi; R Ban; S Ogawa; H Ogihara; H Tamai; T Ogihara
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-05       Impact factor: 5.747

4.  Serum fructosamine and retinopathy of prematurity.

Authors:  Senol Bozdag; Serife Suna Oguz; Tulin Gokmen; Zuhal Tunay; Levent Tok; Nurdan Uras; Omer Erdeve; Ugur Dilmen
Journal:  Indian J Pediatr       Date:  2011-07-06       Impact factor: 1.967

5.  Neonatal red blood cell transfusions: searching for better guidelines.

Authors:  Kavita Kasat; Karen D Hendricks-Muñoz; Pradeep V Mally
Journal:  Blood Transfus       Date:  2011-01       Impact factor: 3.443

Review 6.  Retinopathy of prematurity.

Authors:  E Bossi; F Koerner
Journal:  Intensive Care Med       Date:  1995-03       Impact factor: 17.440

7.  The apparent role of blood transfusions in the development of retinopathy of prematurity.

Authors:  R W Cooke; D Clark; M Hickey-Dwyer; A M Weindling
Journal:  Eur J Pediatr       Date:  1993-10       Impact factor: 3.183

8.  Retinopathy of prematurity: review of a four-year period.

Authors:  B P Cats; K E Tan
Journal:  Br J Ophthalmol       Date:  1985-07       Impact factor: 4.638

9.  A prospective study on hyperglycemia and retinopathy of prematurity.

Authors:  L Mohsen; M Abou-Alam; M El-Dib; M Labib; M Elsada; H Aly
Journal:  J Perinatol       Date:  2014-03-27       Impact factor: 2.521

10.  Wide-field digital imaging based telemedicine for screening for acute retinopathy of prematurity (ROP). Six-year results of a multicentre field study.

Authors:  Birgit Lorenz; Katerina Spasovska; Heike Elflein; Nico Schneider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-22       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.